London, UK and Cambridge, MA, February 3, 2014 – Life sciences management consulting firm Alacrita announced today that Dr Mark Wickham MBA has joined as Partner. He will be based in the London office to further develop Alacrita’s growing business in the medtech sector. Mark has had senior operational roles in large organisations including Smith & Nephew plc, London International Group plc and Bespak plc, as well as experience in founding and leading start-ups bio-del Ltd and B1 Medical Ltd. He also has consulting experience gained at PA Consulting Group and The Technology Partnership.

Mark has supported a broad range of companies and led projects in orthopaedics, sports medicine, cardiology, woundcare, biomaterials, drug delivery (especially respiratory), and diagnostics. His consulting practice focuses on technical and commercial due diligence, innovation strategies and product development and his operational experience covers starting new businesses through to management of large teams of professional staff and facilities.

“I look forward to continuing to advise clients from my new base at Alacrita, as they tackle important challenges and opportunities to grow their businesses,” said Mark Wickham.

"With the addition of Mark as our fourth Partner, Alacrita is better positioned than ever to serve our medtech clients," said Anthony Walker, Alacrita Partner. "Mark will lead our elite team of accomplished medical device professionals supporting our growing client base on both sides of the Atlantic."

About Alacrita

Alacrita is a rapidly growing management consulting firm providing expertise-based services to the pharmaceutical, biotechnology and life science sectors. The firm is supported by an unrivalled team of experts who operate across the spectrum of life sciences. They combine extensive international industry experience (strategic, technical and commercial), broad functional capabilities and a track record of success across the industry.

www.alacrita.com

For more information on how we can assist your biotech or pharmaceutical project, please reach out.

.custom-post-pagination {display: none;}